TOKYO -- A Takeda Pharmaceutical former chairman credited with the company's rapid growth has expressed his opposition to Takeda's $62 billion acquisition of Irish drugmaker Shire, breaking a long silence.
Mergers and acquisitions are necessary in the pharmaceutical industry, "but the Shire deal's risk is high," Kunio Takeda told Nikkei through a representative.
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
to learn how you can update your cookie settings.